For the Inventor, By the Inventor

Enter assignee name

San Mateo, CA, United States of America

Kronos Bio, Inc.

USPTO Granted Patents = 10

% Expired Patents = 10.0

CIPO Patents = 1

Forward Citations = 10

Loading Chart...

Loading Chart...

30 inventors (with patents filed for the assignee):

Jeffrey E Kropf (4 out of 45 patents)

Aaron C Schmitt (4 out of 25 patents)

Seung H Lee (4 out of 37 patents)

4. Scott A Mitchell (4 out of 67 patents)

5. Zhongdong Zhao (4 out of 32 patents)

6. Peter A Blomgren (4 out of 53 patents)

7. Kevin S Currie (4 out of 72 patents)

8. Jianjun Xu (4 out of 40 patents)

9. Sundaramoorthi Swaminathan (3 out of 29 patents)

10. Jennifer R Lo (3 out of 18 patents)

11. Jin-Ming Xiong (3 out of 9 patents)

12. Henry G Morrison (2 out of 21 patents)

13. Peter Chee-Chu Fung (2 out of 4 patents)

14. Paul Robert Hartmeier (2 out of 2 patents)

15. Jesper Alexis Jernelius (2 out of 5 patents)

10 patents: Sort by Forward Citations

1. 12263163 - Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor (2025-04-01),

2. 12152037 - Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor (2024-11-26),

3. 12122781 - Hydrates of polymorphs of 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)-2,3-dihydroimidazo[1,2-a]pyrazin-8-amine bis-mesylate as Syk inhibitors (2024-10-22),

4. 11845754 - Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity (2023-12-19),

5. 11517570 - Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine (2022-12-06),

6. 11384082 - Hydrates of polymorphs of 6-(1H-indazol-6-YL)-N-(4-morpholinophenyl)-2,3-dihydroimidazo[1,2-A]pyrazin-8-amine bisemsylate as Syk inhibitors (2022-07-12),

7. 11339168 - Crystalline forms of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as Syk inhibitors (2022-05-24),

8. 11155560 - Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity (2021-10-26),

9. 10842803 - Imidazopyridines Syk inhibitors (2020-11-24),

10. 10828299 - Crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine (2020-11-10),

Company Overview

Kronos Bio, Inc. is a biotechnology company based in San Mateo, California, focused on developing innovative therapies for cancer treatment. The company specializes in the discovery and development of small molecule drugs that target specific transcription factors and signaling pathways implicated in cancer. By leveraging advanced research techniques and a deep understanding of cancer biology, Kronos Bio aims to address unmet medical needs and improve patient outcomes in oncology.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

10 Patents

#78 in San Mateo, CA

#7,118 in California

#29,882 in US

#56,092 in the World

San Mateo, CA, United States of America

Kronos Bio, Inc.

Forward Citations = 10

30 inventors:

Jeffrey E Kropf (4 out of 45 patents)

Aaron C Schmitt (4 out of 25 patents)

Seung H Lee (4 out of 37 patents)

4. Scott A Mitchell (4 out of 67 patents)

5. Zhongdong Zhao (4 out of 32 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Kronos Bio, Inc.. Retrieved from https://idiyas.com/company/kronos-bio

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…